Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlotte Genestet

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Microorganisms|July 27, 2022
<i>Mycobacterium tuberculosis</i> Diversity Exploration: A Way to Serve the Three Main Weapons against Epidemics, Hygiene, Vaccine Development and ChemotherapyGuislaine Refrégier, Charlotte Genestet
Frontiers in Medicine|October 3, 2022
Opti-4TB: A protocol for a prospective cohort study evaluating the performance of new biomarkers for active tuberculosis outcome predictionOlivier Bahuaud, Charlotte Genestet, Jonathan Hoffmann, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 4, 2026
Nocardia antimicrobial susceptibility testing by microdilution: evaluation of ready-to-use plate including tedizolid and meropenemMateo Dutarte, Charlotte Genestet, Gérard Lina, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2017
Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using <i>In Vitro</i> Experiments and Response-Surface ModelingCharlotte Genestet, Florence Ader, Catherine Pichat, et al.
Annals of Clinical Microbiology and Antimicrobials|February 28, 2025
In vitro activity of rifampicin, rifapentine and rifabutin in combination with their 25-deacetyl-metabolites against various Mycobacterium tuberculosis lineagesCharlotte Genestet, Chloé Bourg, Elisabeth Hodille, et al.
Clinical Pharmacokinetics|January 27, 2025
Exposure to Rifampicin and its Metabolite 25-Deacetylrifampicin Rapidly Decreases During Tuberculosis TherapySylvain Goutelle, Olivier Bahuaud, Charlotte Genestet, et al.
Tuberculosis (Edinburgh, Scotland)|July 15, 2024
Optimization of Mycobacterium tuberculosis DNA processing prior to whole genome sequencingSamira Dziri, Julie Marin, Pauline Quagliaro, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 12, 2024
Retrospective and prospective evaluation of the FluoroType®-Mycobacteria VER 1.0 assay for the identification of mycobacteria from cultures in a French centerLisa Piasecki, Charlotte Genestet, Yvonne Benito, et al.
Free Radical Biology & Medicine|June 15, 2014
Scavenging of reactive oxygen species by tryptophan metabolites helps Pseudomonas aeruginosa escape neutrophil killingCharlotte Genestet, Audrey Le Gouellec, Hichem Chaker, et al.
International Journal of Molecular Sciences|October 14, 2022
Development, Evaluation, and Implementation of a House-Made Targeted Next-Generation Sequencing Spoligotyping in a French LaboratoryCharlotte Genestet, Yannick Baffert, Maxime Vallée, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Microorganisms|July 27, 2022
<i>Mycobacterium tuberculosis</i> Diversity Exploration: A Way to Serve the Three Main Weapons against Epidemics, Hygiene, Vaccine Development and ChemotherapyGuislaine Refrégier, Charlotte Genestet
Frontiers in Medicine|October 3, 2022
Opti-4TB: A protocol for a prospective cohort study evaluating the performance of new biomarkers for active tuberculosis outcome predictionOlivier Bahuaud, Charlotte Genestet, Jonathan Hoffmann, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 4, 2026
Nocardia antimicrobial susceptibility testing by microdilution: evaluation of ready-to-use plate including tedizolid and meropenemMateo Dutarte, Charlotte Genestet, Gérard Lina, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2017
Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using <i>In Vitro</i> Experiments and Response-Surface ModelingCharlotte Genestet, Florence Ader, Catherine Pichat, et al.
Annals of Clinical Microbiology and Antimicrobials|February 28, 2025
In vitro activity of rifampicin, rifapentine and rifabutin in combination with their 25-deacetyl-metabolites against various Mycobacterium tuberculosis lineagesCharlotte Genestet, Chloé Bourg, Elisabeth Hodille, et al.
Clinical Pharmacokinetics|January 27, 2025
Exposure to Rifampicin and its Metabolite 25-Deacetylrifampicin Rapidly Decreases During Tuberculosis TherapySylvain Goutelle, Olivier Bahuaud, Charlotte Genestet, et al.
Tuberculosis (Edinburgh, Scotland)|July 15, 2024
Optimization of Mycobacterium tuberculosis DNA processing prior to whole genome sequencingSamira Dziri, Julie Marin, Pauline Quagliaro, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 12, 2024
Retrospective and prospective evaluation of the FluoroType®-Mycobacteria VER 1.0 assay for the identification of mycobacteria from cultures in a French centerLisa Piasecki, Charlotte Genestet, Yvonne Benito, et al.
Free Radical Biology & Medicine|June 15, 2014
Scavenging of reactive oxygen species by tryptophan metabolites helps Pseudomonas aeruginosa escape neutrophil killingCharlotte Genestet, Audrey Le Gouellec, Hichem Chaker, et al.
International Journal of Molecular Sciences|October 14, 2022
Development, Evaluation, and Implementation of a House-Made Targeted Next-Generation Sequencing Spoligotyping in a French LaboratoryCharlotte Genestet, Yannick Baffert, Maxime Vallée, et al.
Pageof 3